MedTrace Logo

Study of Late Fetal Loss in Poitou-Charentes. GYNE-COVID

NCT04387253 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2022-07-12

No results posted yet for this study

Summary

Maternal-fetal transmission in the second or third trimester of pregnancy of the SARS-COV-2 virus could explain some late fetal losses.

Finding a cause in the context of fetal loss is essential for parents and caregivers. It helps to understand the history of the disease, to address the possible risk of a recurrence and to plan for future pregnancies.

If the maternal-fetal transmission of COVID 19 is confirmed and that it is responsible for obstetric complications, a preventive action could be proposed to the patients by the preconception vaccination.

The investigators are seeking to clarify the frequency of this transmission is information awaited by caregivers, women, couples in particular when the latter are in distress from late fetal loss.

Conditions

  • Identification of the Mother or Fetus Contamination by SARS Cov-2
  • Research the Presence of Viruses at Different Sites of the Mother and the Fetus or Father
  • The Survey Builds on a Network Work Already Organized Around the CPDPN of Poitou-Charentes
  • Analysis Laboratories of the Poitiers CHU

Interventions

DIAGNOSTIC_TEST

Identification by PCR of the SARS-COV-2 virus in samples taken from the fetus

Identification by PCR of the SARS-COV-2 virus in samples taken from the fetus Presence of SARS-COV-2 virus in samples taken from mother and father. Circulating anti-SARS-COV-2 antibodies in the mother.

Sponsors & Collaborators

  • Poitiers University Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-05-23
Primary Completion
2022-06-17
Completion
2022-06-17

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04387253 on ClinicalTrials.gov